Highest-materiality recent filing
MiMedx Q2 net sales $64M (-35% YoY); to acquire Sanara MedTech for ~$350M
Net sales $64M vs $99M YoY; net loss $15M vs net income $10M YoY.
MiMedx to acquire Sanara MedTech for $35/share in cash and stock, ~$350M enterprise value
MiMedx to acquire Sanara MedTech for $35 per share ($33 cash + 0.4735 MDXG shares), total enterprise value ~$350M.
MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M
Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.
MiMedx Announces Restructuring and $40M Annual Cost Reduction Initiative
Eliminated Chief Operating Officer position held by Ricci Whitlow; her departure effective immediately.
MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback
Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.
MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance
Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.
MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits
Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.
MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook
Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).
Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.
MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits
GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.
MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%
Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.
MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)
Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.
FDA rules AXIOFILL does not qualify as HCT/P; MiMedx to sue, reiterates 2024 guidance
FDA determined AXIOFILL does not meet HCT/P criteria under Section 361, treating it as a 351 biologic product.
MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth
Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.
MiMedx closes $95M senior secured credit facilities; reduces interest expense
New facilities: $75M revolver + $20M term loan, due Jan 2029.
MiMedx Q3 net sales up 20.7% to $81.7M, GAAP net income $8.5M, raises FY outlook
Q3 net sales $81.7M (+20.7% YoY); GAAP net income $8.5M vs loss $8.4M prior year.
MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens
Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).
MiMedx appoints Doug Rice as CFO; Peter Carlson resigns effective July 5, 2023
Doug Rice, former CFO of Orthofix Medical, named CFO effective July 5, 2023.
MiMedx suspends KOA program, focuses on wound care, raises 2023 sales guidance to mid-teens growth
Suspending knee osteoarthritis program and disbanding Regenerative Medicine unit; President Dr. Stein departing.
MiMedx Q1 net sales $71.7M (+21.7% YoY); net loss narrows to $5.0M; Adj. EBITDA $5.5M
Net sales $71.7M in Q1 2023, up 21.7% from $58.9M in Q1 2022.
MiMedx CFO Peter Carlson resigns; search for successor initiated
CFO Peter M. Carlson leaves to pursue other opportunities; effective date to be mutually agreed.
MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed
Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.
MiMedx appoints ex-BioTelemetry CEO Joseph H. Capper as CEO, effective Jan 27
Appointed Joseph H. Capper as CEO and director, effective Jan 27, 2023; Todd Newton steps down as interim CEO but remains on board.
MiMedx reaffirms Q4/FY2022 sales; warns of Medicare reimbursement risk for skin substitutes
Q4 2022 net sales expected $73M-$76M; FY2022 $266M-$269M, unchanged from Nov 2022 guidance.
MiMedx appoints Ricci S. Whitlow as COO effective January 3, 2023
Whitlow most recently President, Clinical Supply Services at Catalent; 30+ years MedTech experience.
MiMedx President Rohit Kashyap resigns effective Jan 3, 2023
Dr. Rohit Kashyap, President of Wound Care and Surgical, tendered resignation effective January 3, 2023.
MiMedx obtains exclusive worldwide license to Turn's PermaFusion antimicrobial platform for wound, burn, and surgical fields.
MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products
Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.
MiMedx appoints Todd Newton as Interim CEO; former CEO Wright receives $3.1M severance
K. Todd Newton named interim CEO effective Sept 14, 2022; monthly salary of $54,166.67.
MiMedx appoints Todd Newton interim CEO; 2022 revenue growth outlook at low end of prior range
Timothy R. Wright terminated as CEO effective immediately; K. Todd Newton appointed interim CEO.
On February 29, 2024, the Board of Directors (the “ Board ”) of MiMedx Group, Inc. (the “ Company ”), approved an increase in the size of the Board to eleven members and appointed two new members, Ms. Tiffany P. Olson and Ms. Dorothy E. Puhy, to the Board, effective March 1, 2024.
On February 29, 2024, the Board of Directors (the “ Board ”) of MiMedx Group, Inc. (the “ Company ”), approved an increase in the size of the Board to eleven members and appointed two new members, Ms. Tiffany P. Olson and Ms. Dorothy E. Puhy, to the Board, effective March 1, 2024.
As a result of this shared decision, Mr. Phelan decided to retire, also effective September 1, 2023.
After discussions with MiMedx Group, Inc. (the “Company”), including Doug Rice, the Company’s recently appointed Chief Financial Officer, William Phelan, who had previously been serving as Chief Accounting Officer, and the Company agreed that it was in the Company’s best interests to combine the roles of Chief Financial Officer and Chief Accounting Officer into a single position, which Mr. Rice assumed, effective on September 1, 2023.
Doug Rice has been appointed to serve as Chief Financial Officer of the Company, effective on July 5, 2023.
Peter Carlson submitted his resignation as Chief Financial Officer of the Company.
Dr. Robert Stein’s position as President of the Company’s Regenerative Medicine business unit was eliminated as part of the realignment, and he will be departing from the Company.
On March 23, 2023, MiMedx Group, Inc. (the “Company”), announced that Peter M. Carlson, its Chief Financial Officer, had informed the Company of his decision to leave the Company to pursue other opportunities at an effective date to be mutually agreed upon.
Also on January 30, 2023, the Company announced that K. Todd Newton will step down and cease to serve as Interim Chief Executive Officer of the Company, also effective on January 27, 2023, but will remain on the Board.
On January 30, 2023, MiMedx Group, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed Joseph H. Capper to serve as Chief Executive Officer of the Company, effective on January 27, 2023.
Mr. Capper will also be appointed to the Board of Directors effective on the commencement of his employment with the Company.
On January 3, 2023, MiMedx Group, Inc. (the “Company”) appointed Ricci S. Whitlow as its Executive Vice President and Chief Operating Officer, and issued a press release in connection therewith, which is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein.
Max materiality 0.90 · Median 0.60 · Most common event earnings